Vertex Pharmaceuticals Announces Phase 3 Study of KALYDECO in Children Ages 6 to 11 with a Specific Type of Cystic Fibrosis Showed Significant Improvements in Lung Function and Other Measures of Disease Sustained Through 48 Weeks   